The egg-based quadrivalent influenza vaccines recommended by the Scientific Committee on Vaccine Preventable Diseases (SCVPD) for the 2023-24 season contain the following:
The recombinant-based quadrivalent influenza vaccines recommended by the SCVPD for the 2023-24 season contain the following:
If trivalent influenza vaccine is being used, the influenza B component shall contain a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Seasonal influenza vaccine is very safe and usually well tolerated apart from occasional soreness, redness or swelling at the injection site (inactivated vaccine and recombinant vaccine). Some recipients may experience fever, muscle pain, and tiredness.
An adverse event is a health problem that is reported after someone gets vaccinated. It may or may not have been caused by the vaccine. Some of these events may occur by chance during the post-vaccination period and are unrelated to vaccination. Report of adverse event does not mean that a vaccine caused the event.
Number of GBS (within the period of 5 days and 6 weeks after vaccination) and other serious neurological adverse events reported among vaccinated person in 2023/24 season (as of 12 noon, 22 April 2024):
|
Guillain-Barré Syndrome |
Other serious neurological adverse events |
|
1 |
0 |
For the number of newly admitted GBS cases in Hong Kong, please click here.